Physician Assistant, Medical · Williamsville, NY
NPI
1346432333
Since 2007
Specialty
Physician Assistant, Medical
Code 363AM0700X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
325 Essjay Rd Ste 170
Williamsville, NY, 14221
Phone (716) 631-2517
Groups this clinician bills Medicare through
Medicare paid, 2024
$23K
675 services
Medicare patients, 2024
207
Average age 72
Drug cost, 2024
$1.2M
2,921 prescriptions
Company payments, 2025
$1,029
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark R Kuczmanski was code 99213 (office e&m - established), 241 times for 166 patients. In total Mark R Kuczmanski billed 675 services in 28 codes, and Medicare paid $23K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-12-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 241 | 166 | $51.68 | $12K |
| 99204 Office E&M - New | Office | 45 | 45 | $101.51 | $4,568 |
By year: 2022 $18K for 317 services; 2023 $19K for 339 services; 2024 $23K for 675 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mark R Kuczmanski prescribed most often to Medicare patients was Famotidine, with 798 prescriptions and refills. In total Mark R Kuczmanski wrote 2,921 Medicare prescriptions that cost $1.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Famotidine Generic | 798 | 1,300 | 248 | $13K |
| Omeprazole Generic | 470 | 869 | 148 | $5,714 |
| Pantoprazole Sodium Generic | 434 | 815 | 139 | $6,142 |
| Dicyclomine Hcl Generic | 212 | 242 | 89 | $4,391 |
| Linzess Linaclotide | 131 | 143 | 30 | $75K |
| Mesalamine Generic | 68 | 114 | 17 | $49K |
| Prednisone Generic | 62 | 78 | 21 | $454 |
| Humira(Cf) Pen Adalimumab | 60 | 66 | 11 | $511K |
| Cholestyramine Cholestyramine (With Sugar) | 48 | 63 | 17 | $6,407 |
| Ursodiol Generic | 47 | 97 | 14 | $8,882 |
| Esomeprazole Magnesium Generic | 46 | 82 | Under 11 | $927 |
| Pentasa Mesalamine | 30 | 38 | Under 11 | $42K |
| Xifaxan Rifaximin | 29 | 29 | 12 | $80K |
| Balsalazide Disodium Generic | 28 | 33 | Under 11 | $2,885 |
| Ondansetron Hcl Generic | 26 | 28 | 18 | $232 |
Brand drugs: 388 claims; generic drugs: 2,533 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark R Kuczmanski $1,029 ($1,029 in general payments such as food, travel and fees) from 8 companies. The largest payer was Abbvie Inc. with $314.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 22 | $314 |
| Janssen Biotech, Inc. JNJ | 20 | $273 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 29 | $252 |
| Phathom Pharmaceuticals, Inc. PHAT | 2 | $67.31 |
| Pfizer Inc. PFE | 3 | $50.11 |
| Novo Nordisk Inc NVO | 2 | $34.22 |
| Aimmune Therapeutics, Inc. | 1 | $23.77 |
| Celltrion USA Inc. 068270.KS | 1 | $14.74 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.